High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study

Figures & data

Table 1. Comparison of the demographic characteristics, primary diseases and vaccine responses of the responder and non-responder patient groups.

	Non-Responder		Responder		p
	n	%	n	%
Gender
Male	27	47,4	30	52,6	0,899
Famale	24	46,2	28	53,8
Age
18–40	19	45,2	23	54,8	0,369
41–64	28	45,2	34	54,8
≥65	4	80	1	20
BMI
<30	33	46,5	38	53,5	0,634
≥ 30	15	51,7	14	48,3
Smoking status
Non-smoker	29	48,3	31	51,7	0,721
Smoker	22	44,9	27	55,1
Disease
Psoriasis	37	44,6	46	55,4	0,712
Crohn’s disease	7	58,3	5	41,7
Rheumatoid arthritis	4	66,7	2	33,3
Ulcerative colitis	1	33,3	2	66,7
Hidradenitis supurativa	2	66,7	1	33,3
Behcet’s disease	0	0,0	1	100,0
Ankylosing spondylitis	0	0,0	1	100,0
Total	51	46,8	58	53,2

BMI: body mass index

Table 2. Vaccine response rates according to the immunomodulatory drug used.

	Non-Responder n (%)	Responder n (%)	p
Adalimumab	32 (51,6)	30 (48,4)	0,246
Ustekinumab	7 (28)	18 (72)	0,032
İnfliximab	10 (83,3)	2 (16,7)	0,007
Etanercept	1 (11,1)	8 (88,9)	0,035
Golimumab	1 (100)	0 (0)

Table 3. Comparison of vaccine response rates in standard and high dose HBV vaccinations.

	Non-Responder	Responder	p
Standard dose vaccination group n (%)	37 (50,7)	36 (49,3)	0,246
High dose vaccination group n (%)	14 (38,9)	22 (61,1)
Total	51 (46,8)	58 (53,2)

Table 4. Comparison of standard and high dose vaccine responses according to the immunomodulatory drug used.

	Non-Responder		Responder		p
	Standard dose n (%)	High dose n (%)	Standard dose n (%)	High dose n (%)
Adalimumab	22 (68,8)	10 (31,3)	22 (73,3)	8 (26,7)	0,691
Ustekinumab	5 (71,4)	2 (28,6)	10 (55,6)	8 (44,4)	0,659
İnflixumab	9 (90)	1 (10)	1 (50)	1 (50)	0,318
Etanercept	1 (100)	0 (0)	3 (37,5)	5 (62,5)	0,444
Golimumab	0 (0)	1 (100)	0 (0)	0 (0)	-

Figure 1. Comparison of serum anti-HBs titers in standard dose and high dose vaccine groups.